Norwegian biotechnology firm Nordic Nanovector has secured fast-track status from the US Food and Drug Administration (FDA) for its Betalutin (177Lu-lilotomab satetraxetan) drug to treat follicular lymphoma (FL).

Betalutin is an anti-CD37 antibody (lilotomab) linked to a low-intensity radionuclide (lutetium-177). It gets internalised in cancer cells and prolonged exposure of the nucleus to radiation kills DNA resulting in the death of the tumour cell.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The drug also has a crossfire effect that destroys surrounding cancer cells, however, it is limited to a radius of 40 cells.

Nordic Nanovector is seeking approval for the use of the drug in relapsed or refractory FL patients who have received at least two previous systemic therapies.

Nordic Nanovector chief medical officer Lisa Rojkjaer said: “This designation is based on the promising safety and preliminary efficacy data in patients with relapsed/refractory indolent non-Hodgkin’s lymphoma from the first part of the LYMRIT 37-01 study, and highlights the potential of Betalutin to be a new therapeutic option for these patients.

“This designation highlights the potential of Betalutin to be a new therapeutic option for these patients.”

“We are now focusing the PARADIGME trial on third line (3L) CD20-refractory FL patients, a population in urgent need of new therapies, and look forward to working with the FDA to advance the development of Betalutin.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In the Phase I/IIa LYMRIT 37-01 trial, Betalutin is reported to have shown positive efficacy and tolerability profile in subjects suffering from relapsed or refractory FL.

The global, randomised Phase IIb PARADIGME trial is designed to evaluate 15MBq/kg and 20MBq/kg Betalutin regimens in around 130 patients at 80-85 clinical sites across approximately 20 countries.

While the primary endpoint for this trial is overall response rate (ORR), its secondary endpoints include duration of response (DoR), overall survival (OS), safety, progression free survival (PFS) and quality of life.